share_log

T2 Biosystems | 8-K: T2 Biosystems Announces Second Quarter 2024 Financial Results

T2 Biosystems | 8-K: T2 Biosystems Announces Second Quarter 2024 Financial Results

T2 Biosystems | 8-K：T2 Biosystems 公布2024年第二季度财务业绩
美股SEC公告 ·  2024/07/30 05:05

Moomoo AI 已提取核心信息

T2 Biosystems achieved Q2 2024 total revenue of $2.0 million, with record quarterly sepsis test revenue growing 27% YoY led by T2Bacteria and T2Resistance panel sales. Loss from operations improved 27% to $9.6 million compared to $13.1 million in Q2 2023. Net loss was $9.2 million ($0.66 per share) versus $6.3 million ($7.84 per share) last year. Cash position stood at $4.2 million as of June 30, 2024.The company executed contracts for 2 T2Dx Instruments internationally in Q2 and secured 6 additional instrument contracts in July 2024. Strategic progress includes signing distribution agreements in Qatar, Hong Kong, Malaysia, Indonesia, and Macau. The company strengthened its balance sheet by converting $30.0 million of CRG term loan debt into equity, reducing total debt and quarterly interest payments by approximately 80%.T2 Biosystems completed clinical studies for T2Lyme Panel launch as a laboratory developed test in Q3 2024 and submitted FDA 510(k) for expanded T2Candida Panel pediatric testing. The company maintains its 2024 guidance for sepsis product revenue of $10.0-11.0 million, representing 49-64% growth YoY.
T2 Biosystems achieved Q2 2024 total revenue of $2.0 million, with record quarterly sepsis test revenue growing 27% YoY led by T2Bacteria and T2Resistance panel sales. Loss from operations improved 27% to $9.6 million compared to $13.1 million in Q2 2023. Net loss was $9.2 million ($0.66 per share) versus $6.3 million ($7.84 per share) last year. Cash position stood at $4.2 million as of June 30, 2024.The company executed contracts for 2 T2Dx Instruments internationally in Q2 and secured 6 additional instrument contracts in July 2024. Strategic progress includes signing distribution agreements in Qatar, Hong Kong, Malaysia, Indonesia, and Macau. The company strengthened its balance sheet by converting $30.0 million of CRG term loan debt into equity, reducing total debt and quarterly interest payments by approximately 80%.T2 Biosystems completed clinical studies for T2Lyme Panel launch as a laboratory developed test in Q3 2024 and submitted FDA 510(k) for expanded T2Candida Panel pediatric testing. The company maintains its 2024 guidance for sepsis product revenue of $10.0-11.0 million, representing 49-64% growth YoY.
T2 Biosystems在2024年第二季度实现了200万美元的总营业收入，季度败血症检测收入创下新高，受T2Bacteria和T2支撑位面板销售的推动同比增长27%。运营损失改善了27%，降至960万美元，而2023年第二季度为1310万美元。净亏损为920万美元（每股0.66美元），而去年为630万美元（每股7.84美元）。截至2024年6月30日，现金储备为420万美元。该公司在第二季度国际上签署了2份T2Dx仪器合同，并在2024年7月额外获得了6份仪器合同。战略进展包括在卡塔尔、香港、马来西亚、印度尼西亚和澳门签署分销协议。该公司通过将3000万美元的CRG定期贷款债务转换为股权，...展开全部
T2 Biosystems在2024年第二季度实现了200万美元的总营业收入，季度败血症检测收入创下新高，受T2Bacteria和T2支撑位面板销售的推动同比增长27%。运营损失改善了27%，降至960万美元，而2023年第二季度为1310万美元。净亏损为920万美元（每股0.66美元），而去年为630万美元（每股7.84美元）。截至2024年6月30日，现金储备为420万美元。该公司在第二季度国际上签署了2份T2Dx仪器合同，并在2024年7月额外获得了6份仪器合同。战略进展包括在卡塔尔、香港、马来西亚、印度尼西亚和澳门签署分销协议。该公司通过将3000万美元的CRG定期贷款债务转换为股权，增强了其资产负债表，减少了约80%的总债务和季度利息支付。T2 Biosystems已完成T2Lyme面板作为实验室开发测试的临床研究，并提交了FDA 510(k)申请，扩展T2Candida面板的儿科检测。该公司维持其2024年败血症产品营业收入的指引为1000-1100万美元，同比增长49-64%。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    英伟达
    NVDA
    -- 105.910
    特斯拉
    TSLA
    -- 255.910
    Palantir
    PLTR
    -- 83.860
    亚马逊
    AMZN
    -- 189.085
    谷歌-C
    GOOG
    -- 155.085
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日